|
|
Chloé C. Féral, David M. Rose, Jaewon Han, Norma Fox, Gregg J. Silverman, Kenneth Kaushansky, Mark H. Ginsberg
J Clin Invest. 2006;
116(3):715
doi:10.1172/JCI26091
Abstract |
Full text
| PDF

A
ntagonists to α4 integrin show promise for several autoimmune and inflammatory diseases but may exhibit mechanism-based toxicities. We tested the capacity of blockade of α4 integrin signaling to perturb functions involved in inflammation, while limiting potential adverse effects. We generated and characterized mice bearing a Y991A mutation in α4 integrin [α4(Y991A) mice], which blocks paxillin binding and inhibits α4 integrin signals that support leukocyte migration. In contrast to the embryonic-lethal phenotype of α4 integrin–null mice, mice bearing the α4(Y991A) mutation were viable and fertile; however, they exhibited defective recruitment of mononuclear leukocytes into thioglycollate-induced peritonitis. α4 Integrins are essential for definitive hematopoiesis; however, the α4(Y991A) mice had intact lymphohematopoiesis and, with the exception of reduced Peyer’s patches, normal architecture and cellularity of secondary lymphoid tissues. We conclude that interference with α4 integrin signaling can selectively impair mononuclear leukocyte recruitment to sites of inflammation while sparing vital functions of α4 integrins in development and hematopoiesis.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(10)
| Title and authors |
Publication |
Year |
RNAi-based therapeutic strategies for metabolic disease
Michael P. Czech, Myriam Aouadi, Gregory J. Tesz
|
Nat Rev Endocrinol
|
2011 |
Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
Michael C. Schmid, Christie J. Avraamides, Holly C. Dippold, Irene Franco, Philippe Foubert, Lesley G. Ellies, Lissette M. Acevedo, Joan R.E. Manglicmot, Xiaodan Song, Wolfgang Wrasidlo, Sara L. Blair, Mark H. Ginsberg, David A. Cheresh, Emilio Hirsch, Seth J. Field, Judith A. Varner
|
Cancer Cell
|
2011 |
From the Cover: Abl-interactor-1 (Abi1) has a role in cardiovascular and placental development and is a binding partner of the 4 integrin
C. Ring, M. H. Ginsberg, J. Haling, A. M. Pendergast
|
Proceedings of the National Academy of Sciences
|
2010 |
The Ins and Outs of Leukocyte Integrin Signaling
Clare L. Abram, Clifford A. Lowell
|
Annu. Rev. Immunol.
|
2009 |
Angiogenesis in inflammatory bowel disease
I. D. Pousa, J. Maté, J. P. Gisbert
|
European Journal of Clinical Investigation
|
2008 |
Getting to the site of inflammation: the leukocyte adhesion cascade updated
Klaus Ley, Carlo Laudanna, Myron I. Cybulsky, Sussan Nourshargh
|
Nat Rev Immunol
|
2007 |
α4 Integrins are Type I cAMP-dependent protein kinase-anchoring proteins
Chinten James Lim, Jaewon Han, Nima Yousefi, Yuliang Ma, Paul S. Amieux, G. Stanley McKnight, Susan S. Taylor, Mark H. Ginsberg
|
Nat Cell Biol
|
2007 |
Small GTPases and LFA-1 reciprocally modulate adhesion and signaling
Adam Mor, Michael L. Dustin, Mark R. Philips
|
Immunological Reviews
|
2007 |
Integrin antagonists as therapeutics for inflammatory diseases
Peter Vanderslice, Darren G Woodside
|
Expert Opin. Investig. Drugs
|
2006 |
β1 integrins: zip codes and signaling relay for blood cells
Michael Sixt, Martina Bauer, Tim Lämmermann, Reinhard Fässler
|
Current Opinion in Cell Biology
|
2006 |
|